CVAC CureVac N.V.

FDA Catalyst Company
16.75
+1.3  (+8%)
Previous Close 15.45
Open 16.27
52 Week Low 14.2
52 Week High 125.66
Market Cap $3,134,272,027
Shares 187,120,718
Float 72,073,776
Enterprise Value $2,113,262,473
Volume 286,936
Av. Daily Volume 506,468
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
JMP Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/22/2022
B of A Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/21/2022
JMP Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/18/2022
Deutsche Bank Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 10/22/2021
B of A Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 06/17/2021
Guggenheim Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/26/2021
Credit Suisse Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 12/10/2020

Latest News

  1. - Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone
    - Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, validating mRNA backbone for further variant adaptation
    - Fully recruited Phase 1 dose-escalation study in influenza with differentiated multivalent vaccine candidate, CVSQIV, confirmed good tolerability profile across all doses
    - Bivalent approach for combined Beta/Delta-COVID-19 vaccine candidate shows promising preclinical data, with high neutralizing capacity against each variant, as well as against Omicron
    - Increasing momentum in oncology pipeline by focusing on new avenues for T cell activation as well

    View Full Article
  2. TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2021 on Thursday, April 28, 2022. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. EST.

    Conference call and webcast details

    Dial-in numbers to participate in the conference call:

    U.S. Toll-Free: +1-877-407-0989
    International: +1-201-389-0921
    Germany: 0800 182 0040

    The live webcast link can be accessed via the newsroom section of the CureVac website at https://www.curevac.com/en/newsroom/events/

    Corresponding…

    View Full Article
  3. - Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study

    - Demonstrated neutralizing capacity against the Omicron variant in vaccinated animals

    - Technology adaptation for bivalent approach for COVID-19 vaccines potentially allows for broader protection against emerging variants

    TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 21, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation COVID-19 vaccine candidate jointly developed…

    View Full Article
  4. - German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK

    - Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency, contributing to increased pandemic preparedness

    TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 11, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), and GSK today announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup period of…

    View Full Article
    • Phase 1 dose-escalation study started at clinical sites in the U.S.
    • Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases

    TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 30, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac's second-generation mRNA…

    View Full Article
View All CureVac N.V. News